Zoghbi Sandra, Drouin Emeline, Claustre Jean, Bara Jacques, Scoazec Jean-Yves, Plaisancié Pascale
INSERM, U45, Lyon, IFR62, University Claude Bernard Lyon I, Faculté de Médecine R. Laennec, Lyon 69372, France.
Int J Oncol. 2007 Feb;30(2):489-97.
Our study was performed to sequentially analyze the expression of the intestinal mucin MUC2 and of the gastric mucin MUC5AC as indicators during progression of preneoplastic biomarkers in rat colon. F344 rats were sacrificed 2, 4, 8, 12, 24 and 36 weeks after injection of 1,2-dimethylhydrazine (DMH, 200 mg/kg, i.p.). The expression of MUC2 and of MUC5AC was studied by immunohistochemistry in preneoplastic lesions classified in two categories: histologically altered foci (HAF) and beta-catenin accumulated crypts (BCAC). HAF appeared 4 weeks after DMH injection. Their crypt multiplicity stagnated with time (3-4 crypts/foci) but gastric MUC5AC mucin was always observed in some goblet cells of the lesions of this category. In contrast, MUC2-immunostaining was not modified compared to the adjacent crypts. Double-immunofluorescence revealed that goblet cells which produced MUC5AC continued to express MUC2. In BCAC, crypt multiplicity and mucin expression strongly evolved with time. These lesions were observed only 8 weeks after DMH-injection. At this stage, 20% of BCAC showed a decreased MUC2 expression and 33% were MUC5AC immunopositive. At the 36-week point, 43% of BCAC had a reduced MUC2 staining and 90% were positive for MUC5AC. This immunopositivity was often observed in all the cells of these lesions. Seldom, some BCAC were depleted at the same time in MUC2 and in MUC5AC. Similar alterations in mucin expression were observed in human colonic pre-neoplastic lesions. These findings suggest that a decrease in MUC2 expression and staining of MUC5AC in non-goblet-like cells predicts histological progression of preneoplastic lesions.
我们开展本研究,旨在对大鼠结肠肿瘤前生物标志物进展过程中肠道黏蛋白MUC2和胃黏蛋白MUC5AC的表达进行序贯分析。注射1,2 - 二甲基肼(DMH,200 mg/kg,腹腔注射)后2、4、8、12、24和36周处死F344大鼠。通过免疫组织化学研究MUC2和MUC5AC在两类肿瘤前病变中的表达:组织学改变灶(HAF)和β - 连环蛋白积聚隐窝(BCAC)。HAF在DMH注射后4周出现。其隐窝多倍体随时间停滞(3 - 4个隐窝/病灶),但在这类病变的一些杯状细胞中总是能观察到胃MUC5AC黏蛋白。相比之下,与相邻隐窝相比,MUC2免疫染色未改变。双重免疫荧光显示产生MUC5AC的杯状细胞继续表达MUC2。在BCAC中,隐窝多倍体和黏蛋白表达随时间强烈变化。这些病变仅在DMH注射后8周观察到。在此阶段,20%的BCAC显示MUC2表达降低,33%为MUC5AC免疫阳性。在36周时,43%的BCAC的MUC2染色减少,90%为MUC5AC阳性。这种免疫阳性在这些病变的所有细胞中经常观察到。很少有一些BCAC同时出现MUC2和MUC5AC缺失。在人类结肠肿瘤前病变中也观察到了类似的黏蛋白表达改变。这些发现表明,非杯状样细胞中MUC2表达降低和MUC5AC染色预示着肿瘤前病变的组织学进展。